Back to News
Market Impact: 0.4
ADMA Biologics Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
ADMA Biologics raised its minimum full-year earnings expectations after third-quarter profit increased, supported by stronger ASCENIV sales and improved manufacturing yields. Competitive pressure weighed on BIVIGAM; the article provides no earnings figures or quantified guidance increase.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
ADMA0.65
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Voters rebuff data centers in every ballot measure except one during the 2026 midterms
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings